Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Accumulated Expenses (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Accumulated Expenses readings, the most recent being $107000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 2040.0% to $107000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $107000.0, a 2040.0% increase, with the full-year FY2025 number at $107000.0, up 2040.0% from a year prior.
  • Accumulated Expenses hit $107000.0 in Q4 2025 for Arcadia Biosciences, up from $5000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.6 million in Q4 2021 to a low of $5000.0 in Q4 2024.
  • Median Accumulated Expenses over the past 5 years was $107000.0 (2025), compared with a mean of $568600.0.
  • Biggest five-year swings in Accumulated Expenses: tumbled 99.63% in 2022 and later surged 18550.0% in 2023.
  • Arcadia Biosciences' Accumulated Expenses stood at $1.6 million in 2021, then tumbled by 99.63% to $6000.0 in 2022, then surged by 18550.0% to $1.1 million in 2023, then tumbled by 99.55% to $5000.0 in 2024, then skyrocketed by 2040.0% to $107000.0 in 2025.
  • The last three reported values for Accumulated Expenses were $107000.0 (Q4 2025), $5000.0 (Q4 2024), and $1.1 million (Q4 2023) per Business Quant data.